PRESCOTT, Ariz. – (July 10, 2008) Imulan BioTherapeutics, LLC (IMULAN) and ProLabs, LTD announced a distribution alliance concerning Lymphocyte T-Cell Immunomodulator (LTCI), the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia.
Dr. Craig Woods, CEO of IMULAN, stated “We are delighted to have aligned with ProLabs to accommodate IMULAN’s growing distribution, marketing, and technical service needs. This is a very synergistic relationship, allowing IMULAN access to premier distribution and representation.”
”The LTCI technology is very exciting for veterinary medicine”, says Steve Schram, President and CEO of ProLabs. “It will offer the veterinarian and the pet owner a more viable option for treatment of these devastating diseases. We are excited to partner with Imulan on the marketing and distribution of this new and differentiated technology”.
About Lymphocyte T-Cell Immunomodulator: Lymphocyte T-Cell Immunomodulator (LTCI) has received a conditional license from the United States Department of Agriculture. Conditional licenses are granted by the United States Department of Agriculture-Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing.
About FeLV and FIV: Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) an infectious retroviral diseases of cats that often result in immune dysfunction. FeLV can be associated with certain forms of feline cancer, including leukemia and lymphoma. All retroviruses, including FeLV, feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV), produce an enzyme, reverse transcriptase, which permits them to insert copies of their own genetic material into host cells.
About IMULAN: Imulan develops unique, precision immune regulating compounds for veterinary medicine. Imulan’s primary focus is on biological strategies treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN’s platforms are currently being developed for feline asthma, feline leukemia virus, feline stomatitis, canine atopic dermatitis, and canine dilated cardiomyopathy. For more information about Imulan, please visit www.imulan.com.
About ProLabs: ProLabs is the ethical division of Agri Labs and is based out of St. Joseph, Missouri. ProLabs is owned by 17 distributors who represent over $2.5B in sales in the United States. ProLabs has been supplying quality, innovative products to veterinarians for over 25 years. For more information about ProLabs, please visit www.ProLabsAnimalhealth.com
For more information contact:
Brian Reardon
ProLabs
800-367-6359
Breardon@agrilabs.com
